Kissei Pharmaceutical Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Kissei PharmaceuticalDer Gewinn des Unternehmens wird voraussichtlich um 3.3% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 4% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich sinken um 3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 4.7% betragen.

Wichtige Informationen

-6.8%

Wachstumsrate der Gewinne

-6.6%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	13.9%
Wachstumsrate der Einnahmen	4.1%
Zukünftige Eigenkapitalrendite	3.7%
Analystenabdeckung	Low
Zuletzt aktualisiert	03 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Kissei Pharmaceutical Co., Ltd. (TSE:4547) Yearly Results: Here's What Analysts Are Forecasting For This Year

May 09

Recent updates

Kissei Pharmaceutical (TSE:4547) Will Pay A Larger Dividend Than Last Year At ¥45.00

Sep 24

Kissei Pharmaceutical (TSE:4547) Is Increasing Its Dividend To ¥45.00

Sep 09

Kissei Pharmaceutical's (TSE:4547) Dividend Will Be Increased To ¥45.00

Jul 25

Kissei Pharmaceutical (TSE:4547) Will Pay A Larger Dividend Than Last Year At ¥45.00

Jul 11

Kissei Pharmaceutical's (TSE:4547) Shareholders May Want To Dig Deeper Than Statutory Profit

May 21

Kissei Pharmaceutical Co., Ltd. (TSE:4547) Yearly Results: Here's What Analysts Are Forecasting For This Year

May 09

Gewinn- und Umsatzwachstumsprognosen

TSE:4547 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (JPY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2027	89,364	8,057	8,414	N/A	3
3/31/2026	85,449	9,067	11,712	N/A	3
3/31/2025	83,855	11,967	5,031	N/A	4
6/30/2024	77,430	12,001	N/A	N/A	N/A
3/31/2024	75,579	11,160	-3,510	-1,677	N/A
12/31/2023	73,717	12,198	N/A	N/A	N/A
9/30/2023	71,607	12,880	-8,350	-5,854	N/A
6/30/2023	70,521	12,158	N/A	N/A	N/A
3/31/2023	67,493	10,528	-9,226	-6,679	N/A
12/31/2022	66,931	12,769	N/A	N/A	N/A
9/30/2022	65,857	10,581	-4,543	-2,556	N/A
6/30/2022	65,031	10,912	N/A	N/A	N/A
3/31/2022	65,381	12,921	-386	1,533	N/A
12/31/2021	66,934	5,664	N/A	N/A	N/A
9/30/2021	69,148	6,555	-2,042	-349	N/A
6/30/2021	69,618	7,204	N/A	N/A	N/A
3/31/2021	69,044	5,285	-4,027	-2,542	N/A
12/31/2020	66,877	5,715	N/A	N/A	N/A
9/30/2020	63,970	5,063	-573	683	N/A
6/30/2020	63,196	2,530	N/A	N/A	N/A
3/31/2020	63,234	2,817	12,632	13,934	N/A
12/31/2019	65,594	4,753	N/A	N/A	N/A
9/30/2019	68,180	4,294	9,189	10,431	N/A
6/30/2019	70,545	4,752	N/A	N/A	N/A
3/31/2019	72,297	5,481	5,013	6,346	N/A
12/31/2018	72,474	5,263	N/A	N/A	N/A
9/30/2018	73,087	8,102	12,159	13,854	N/A
6/30/2018	73,014	9,685	N/A	N/A	N/A
3/31/2018	74,009	9,045	N/A	8,845	N/A
12/31/2017	73,887	8,735	N/A	N/A	N/A
9/30/2017	72,459	8,116	N/A	5,756	N/A
6/30/2017	71,396	6,993	N/A	N/A	N/A
3/31/2017	71,706	7,726	N/A	6,441	N/A
12/31/2016	72,154	6,401	N/A	N/A	N/A
9/30/2016	73,533	8,108	N/A	9,023	N/A
6/30/2016	73,774	8,734	N/A	N/A	N/A
3/31/2016	71,294	8,165	N/A	5,763	N/A
12/31/2015	71,239	8,521	N/A	N/A	N/A
9/30/2015	69,095	6,608	N/A	2,948	N/A
6/30/2015	70,945	7,161	N/A	N/A	N/A
3/31/2015	70,110	7,165	N/A	6,667	N/A
12/31/2014	69,666	7,829	N/A	N/A	N/A
9/30/2014	73,090	9,817	N/A	9,538	N/A
6/30/2014	69,934	8,935	N/A	N/A	N/A
3/31/2014	70,399	9,093	N/A	11,945	N/A
12/31/2013	69,335	9,365	N/A	N/A	N/A
9/30/2013	65,089	6,982	N/A	10,841	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 4547Für die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-3.3% pro Jahr).

Ertrag vs. Markt: 4547Für die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-3.3% pro Jahr).

Hohe Wachstumserträge: 4547Für die nächsten 3 Jahre wird mit einem Rückgang der Erträge gerechnet.

Einnahmen vs. Markt: 4547Die Einnahmen des Unternehmens (3.9% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt JP (4.3% pro Jahr).

Hohe Wachstumseinnahmen: 4547Die Einnahmen des Unternehmens (4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 4547Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (4.7 %).

Kissei Pharmaceutical Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Kissei Pharmaceutical Co., Ltd. (TSE:4547) Yearly Results: Here's What Analysts Are Forecasting For This Year

Price target increased by 7.4% to JP¥3,650

Consensus EPS estimates fall by 10%

Price target increased by 7.1% to JP¥3,400

Kissei Pharmaceutical Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ending September 30, 2023

Price target increased by 8.9% to JP¥3,350

Recent updates

Kissei Pharmaceutical (TSE:4547) Will Pay A Larger Dividend Than Last Year At ¥45.00

Upcoming dividend of JP¥45.00 per share

Kissei Pharmaceutical (TSE:4547) Is Increasing Its Dividend To ¥45.00

Kissei Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 05, 2024

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Kissei Pharmaceutical's (TSE:4547) Dividend Will Be Increased To ¥45.00

Kissei Pharmaceutical (TSE:4547) Will Pay A Larger Dividend Than Last Year At ¥45.00

Final dividend of JP¥45.00 announced

Kissei Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Jul 30, 2024

Kissei Pharmaceutical's (TSE:4547) Shareholders May Want To Dig Deeper Than Statutory Profit

Kissei Pharmaceutical Co., Ltd. (TSE:4547) Yearly Results: Here's What Analysts Are Forecasting For This Year

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024

Kissei Pharmaceutical (TSE:4547) Is Due To Pay A Dividend Of ¥41.00

Upcoming dividend of JP¥41.00 per share

Kissei Pharmaceutical (TSE:4547) Is Due To Pay A Dividend Of ¥41.00

Kissei Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 07, 2024

Kissei Pharmaceutical (TSE:4547) Has Announced A Dividend Of ¥41.00

Third quarter 2024 earnings released: EPS: JP¥59.18 (vs JP¥72.45 in 3Q 2023)

Kissei Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 2024

New major risk - Revenue and earnings growth

Price target increased by 7.4% to JP¥3,650

Kissei Pharmaceutical Co., Ltd. and Maruishi Pharmaceutical Co., Ltd. Announces KORSUVA®? IV Injection Syringe for Dialysis 17.5ug, 25.0ug to Launch in Japan for Treatment of Pruritus in Patients Undergoing Hemodialysis

Consensus EPS estimates fall by 10%

Kissei Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Jan 30, 2024

Now 20% undervalued after recent price drop

Second quarter 2024 earnings released: EPS: JP¥52.66 (vs JP¥36.67 in 2Q 2023)

Now 20% undervalued after recent price drop

Price target increased by 7.1% to JP¥3,400

Kissei Pharmaceutical Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ending September 30, 2023

Upcoming dividend of JP¥41.00 per share at 2.4% yield

Price target increased by 8.9% to JP¥3,350

Kissei Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 07, 2023

Investor sentiment improves as stock rises 17%

New minor risk - Share price stability

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Kissei Pharmaceutical Co., Ltd. Announces Withdrawal of Application for Marketing Approval for Rovatirelin for the Treatment of Spinocerebellar Degeneration in Japan

Full year 2023 earnings: EPS and revenues miss analyst expectations

Kissei Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 22, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Kissei Pharmaceutical Co., Ltd. (TSE:4547) announces an Equity Buyback for 2,000,000 shares, representing 4.34% for ¥6,000 million.

Upcoming dividend of JP¥40.00 per share at 3.1% yield

Kissei Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Third quarter 2023 earnings released: EPS: JP¥72.45 (vs JP¥25.00 in 3Q 2022)

Consensus forecasts updated

Now 20% undervalued

Kissei Pharmaceutical Co., Ltd. Receives Marketing Authorization Approval in Japan for TAVALISSE Tab. 100Mg and 150Mg, an Oral Spleen Tyrosine Kinase Inhibitor

Kissei Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Kissei Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter and Dividend Guidance for Year Ending of March 31, 2023, Payable Date on December 2, 2022

Kissei Pharmaceutical Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ending September 30, 2022

Upcoming dividend of JP¥40.00 per share

Kissei Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Nov 08, 2022

Kissei Pharmaceutical Co., Ltd. Provides Earning Guidance for the First Half Ending September 30, 2022 and Full Year Ending March 31, 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorated over the past week

Consensus forecasts updated

Kissei Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 01, 2022

Consensus forecasts updated

Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2022

Full year 2022 earnings: EPS exceeds analyst expectations

Kissei Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 10, 2022

Upcoming dividend of JP¥28.00 per share

Third quarter 2022 earnings: EPS exceeds analyst expectations

Kissei Pharmaceutical Co., Ltd. Releases Positive Topline Results from Its Phase 3 Clinical Trial in Japan

Second quarter 2022 earnings released: EPS JP¥43.85 (vs JP¥57.18 in 2Q 2021)